Wouter Dercksen

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy

Antoinetta J. M. Beijers, Floortje Mols, Wouter Dercksen et al. · The Journal of Community and Supportive Oncology · 2014 · 99 citations

Pharmacy, Oncology, Pharmacology +13

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane

Dinja T. Kruger, Maurice P.H.M. Jansen, Inge R. Konings et al. · Molecular Oncology · 2019 · 20 citations · Full text

Medicine, Molecular Medicine, Oncology +17

“Dear hair loss”—illness perceptions of female patients with chemotherapy-induced alopecia

Anne Versluis, Kirsten van Alphen, Wouter Dercksen et al. · Supportive Care in Cancer · 2022 · 13 citations

Medicine, Dermatology, Oncology +11

Giving A Face to Chemotherapy-Induced Alopecia: A Feasibility Study on Drawings by Patients

Kirsten van Alphen, Anne Versluis, Wouter Dercksen et al. · Asia-Pacific Journal of Oncology Nursing · 2020 · 12 citations · Full text

Medicine, Dermatology, Oncology +15